Conflicts and dilemmas in prevention of cardiovascular disease. the new, Norwegian Guidelines-a new approach to risk management

European Journal of General Practice

Volumn 18, Issue 1, 2012, Pages 56-62

  Gjelsvik, Bjørn ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Cardiovascular disease; Cost benefit analysis; Guideline development; Prevention; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ALGORITHM; ANTICOAGULANT THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIETARY INTAKE; GENERAL PRACTITIONER; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; NORWAY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SMOKING CESSATION;

ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; HUMANS; MIDDLE AGED; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; RISK MANAGEMENT;

EID: 84857839798     PISSN: 13814788     EISSN: 17511402     Source Type: Journal    
DOI: 10.3109/13814788.2011.650857     Document Type: Review

References (15)

1. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):S1 - 113. (Pubitemid 47339826)
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52. (Pubitemid 39208455)
3. WHO Europe Health for all database. Available at: http://data.euro.who. int/hfadb/ (accessed 25 August 2011).
4. Norheim OF, Gjelsvik B, Kjeldsen SE, Klemsdal TO, Madsen S, Meland E, et al. National guidelines for primary prevention of cardiovascular disease. 10 May 2009. Oslo, Directorate of Health, Oslo, Norway. Available at: http://www.helsedirektoratet.no/publikasjoner/nasjonale-faglige-retningslinjer/ nasjonale-retningslinjer-for-individuell-prim-rforebygging-av-hjerte-og- karsykdommer-399154 (accessed 4 December 2011).
5. Joossens L, Raw M. The tobacco control scale: A new scale to measure country activity. Tob Control 2006;15:247-53. (Pubitemid 43864881)
6. De BG, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10: S1-S10.
7. Getz L, Sigurdsson JA, Hetlevik I, Kirkengen AL, Romundstad S, Holmen J. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: Modelling study. Br Med J. 2005; 331:551.
8. Editorial. A pressure to agree. Lancet 1999;354:787.
9. Norheim OF, Gjelsvik B, Klemsdal TO, Madsen S, Meland E, Narvesen S, et al. Norway's new principles for primary prevention of cardiovascular disease: Age differentiated risk thresholds. Br Med J. 2011;343:d3626.
10. Håheim LL, Fretheim A, Brørs O, Kjeldsen SE, Kristiansen IS, Madsen S, et al. Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions. Oslo: Norwegian Knowledge Center for Health Services; 18 December 2008. Report No.: 20-2008. Available at: http://www.kunnskapssenteret.no/Publikasjoner/ (accessed 4 December 2011).
11. Wisloff T, Norheim OF, Selmer R, Halvorsen S, Kristiansen IS. Health economic evaluation of primary prevention strategies against cardiovascular disease. Oslo: Norwegian knowledge center for the health services; 18 December 2008. Report No.: 34-2008. Available at: http://www.kunnskapssenteret.no/ Publikasjoner/(accessed 4 December 2011).
12. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is 'quality of evidence' and why is it important to clinicians? Br Med J. 2008;3;336:995-8. (Pubitemid 351656090)
13. Selmer R, Lindman AS, Tverdal A, Pedersen JI, Njolstad I, Veierod MB. Model for estimation of cardiovascular risk in Norway. Tidsskr Nor Laegeforen 2008;128:286-90.
14. Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.
15. NORRISK Risk calculator. 1 September 2011. Oslo, Norwegian Health Directorate. Ref Type. Available at: http://rkalk.helsedir.no/default.aspx (accessed 4 December 2011).